(Q51015703)

27 March 2018

title

Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. (English)

1 reference

27 March 2018

author name string

Masakuni Horiguchi

series ordinal

1

1 reference

27 March 2018

Mei Huang

series ordinal

2

1 reference

27 March 2018

Herbert Y Meltzer

series ordinal

3

1 reference

27 March 2018

publication date

25 March 2011

1 reference

27 March 2018

published in

Psychopharmacology

1 reference

27 March 2018

volume

217

1 reference

27 March 2018

issue

1

1 reference

27 March 2018

page(s)

13-24

1 reference

27 March 2018

https://scigraph.springernature.com/pub.10.1007/s00213-011-2251-2

exact match

0 references

cites work

Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Regulation of neurotransmitter release by metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Inhibition of forskolin-stimulated adenylate cyclase activity by 5-HT receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Functional and anatomical aspects of prefrontal pathology in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Identification of a serotonin/glutamate receptor complex implicated in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Molecular targets for treating cognitive dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

The acute effects of NMDA antagonism: from the rodent to the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Metabotropic glutamate receptor signalling in perirhinal cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Reduced prefrontal cortical dopamine, but not acetylcholine, release in vivo after repeated, intermittent phencyclidine administration to rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

A global spatial similarity optimization scheme to track large numbers of dendritic spines in time-lapse confocal microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Lurasidone: a new drug in development for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Is persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Decrements in volume of anterior ventromedial temporal lobe and olfactory dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Double dissociation between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Multiple signals of recognition memory in the medial temporal lobe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

Is it possible to be schizophrenic yet neuropsychologically normal?

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00213-011-2251-2

21 January 2018

12 December 2020

The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats

1 reference

12 December 2020

Pharmacological characterization of metabotropic glutamate receptors in several types of brain cells in primary cultures.

1 reference

12 December 2020

Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex

1 reference

12 December 2020

The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs

1 reference

12 December 2020

NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders

1 reference

12 December 2020

Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.

1 reference

12 December 2020

The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.

1 reference

12 December 2020

Biochemical properties of D1 and D2 dopamine receptors

1 reference

12 December 2020

Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens

1 reference

12 December 2020

Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens

1 reference

12 December 2020

Glutamate and schizophrenia: beyond the dopamine hypothesis

1 reference

12 December 2020

10.1007/S00213-011-2251-2

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018